AVAC's Blog: P-Values

Julie Patterson, an HIV prevention research advocate, discusses her experience earlier this year at the Conference on Retroviruses and Opportunistic Infections (CROI). Initially encouraged by programming geared toward advocate, she came away disappointed, wondering if researchers were listening.

How many doses of oral PrEP must be taken to build up protective levels of drug in the blood? In a webinar, representatives from the CDC and WHO will review their respective guidance development processes and the role, use, contexts and audience for guidance documents. Recording now available.

We've posted several new resources on AVAC.org that you won’t want to miss—analysis of the WHO's recently released guidance on the use of hormonal contraceptives in women at risk of HIV, information about time to protection for PrEP and a blog on building solidarity between African American gay men and African gay men through PrEP.

The WHO issued an updated guidance statement on its recommendations for the use of hormonal contraception by women at high risk of HIV. The update changes the WHO classification of long-acting injectable contraceptives. WHO states “there continues to be evidence of a possible increased risk of HIV among progestogen-only injectable users.” The new guidance is clear that the recommendations are based on women’s right to informed choice in health.